RAPP Projected Dividend Yield
Rapport Therapeutics Inc ( NASDAQ : RAPP )Rapport Therapeutics is a biopharmaceutical company using its receptor associated proteins technology platform focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Co.'s lead therapeutic candidate, RAP-219, is an AMPA receptor designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPg8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy. 21 YEAR PERFORMANCE RESULTS |
RAPP Dividend History Detail RAPP Dividend News RAPP Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |